Safety outcomes from monarchE: Phase 3 study of abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER-2-, node-positive, high risk, early breast cancer

被引：0
|
作者：
Rugo, H. [1 ]
O'Shaughnessy, J. [2 ]
Song, C. [3 ]
Broom, R. [4 ]
Gumus, M. [5 ]
Yamashita, T. [6 ]
San Antonio, B. [7 ]
Shahir, A. [8 ]
Zimmermann, A. [9 ]
Zagouri, F. [10 ]
Reinisch, M. [11 ]
机构：
[1] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA
[2] Baylor Univ, Med Ctr, Texas Oncol, Dallas, TX USA
[3] Fujian Med Univ Union, Fuzhou, Fujian, Peoples R China
[4] Auckland DHB Oncol, Auckland, New Zealand
[5] Arastirma Hastanesi, Istanbul, Turkey
[6] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
[7] Eli Lilly & Co, Madrid, Spain
[8] Eli Lilly & Co, Basingstoke, Hants, England
[9] Eli Lilly & Co, Indianapolis, IN 46285 USA
[10] Gen Hosp Athens Alexandra, Athens, Greece
[11] Brustzentrum Kliniken, Essen, Germany
来源：
BREAST | 2021年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P013
引用
收藏
页码：S23 / S24
页数：2
相关论文
共 50 条
  • [1] Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
    Johnston, Stephen R. D.
    Harbeck, Nadia
    Hegg, Roberto
    Toi, Masakazu
    Martin, Miguel
    Shao, Zhi Min
    Zhang, Qing Yuan
    Martinez Rodriguez, Jorge Luis
    Campone, Mario
    Hamilton, Erika
    Sohn, Joohyuk
    Guarneri, Valentina
    Okada, Morihito
    Boyle, Frances
    Neven, Patrick
    Cortes, Javier
    Huober, Jens
    Wardley, Andrew
    Tolaney, Sara M.
    Cicin, Irfan
    Smith, Ian C.
    Frenzel, Martin
    Headley, Desiree
    Wei, Ran
    San Antonio, Belen
    Hulstijn, Maarten
    Cox, Joanne
    O'Shaughnessy, Joyce
    Rastogi, Priya
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (34) : 3987 - 3998
  • [2] Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer
    Paluch-Shimon, Shani
    Neven, Patrick
    Huober, Jens
    Cicin, Irfan
    Goetz, Matthew P. P.
    Shimizu, Chikako
    Huang, Chiun-Sheng
    Lueck, Hans Joachim
    Beith, Jane
    Tokunaga, Eriko
    Contreras, Jessica Reyes
    de Sant'Ana, Rosane Oliveira
    Wei, Ran
    Shahir, Ashwin
    Nabinger, Sarah C. C.
    Forrester, Tammy
    Johnston, Stephen R. D.
    Harbeck, Nadia
    monarchE Investigators
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [3] Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
    Hamilton, Erika P.
    Kim, Jee Hyun
    Eigeliene, Natalja
    Mavroudis, Dimitrios
    Median, Dragos Mircea
    Marconato, Heloisa
    Shevnia, Serhii
    Ozyilkan, Ozgur
    Puig, Juan Manuel
    Shannon, Catherine M.
    Munoz, Maria
    San Antonio, Belen
    Wei, Ran
    O'Shaughnessy, Joyce
    Johnston, Stephen R. D.
    Guarneri, Valentina
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: a plain language summary of the monarchE study
    D. Johnston, Stephen R.
    Rugo, Hope S.
    Tolaney, Sara M.
    Fernandez, Maria Munoz
    Wei, Ran
    Martin, Miguel
    FUTURE ONCOLOGY, 2024, 20 (28) : 2037 - 2048
  • [5] Efficacy and safety by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in HR+, HER2-early breast cancer
    Paluch-Shimon, S.
    Neven, P.
    Cicin, I.
    Jiang, Z.
    Goetz, M. P.
    Shimizu, C.
    Huang, C. -S.
    Wei, R.
    Nabinger, S. C.
    Forrester, T.
    Harbeck, N.
    SWISS MEDICAL WEEKLY, 2022, 152 : 48S - 48S
  • [6] Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer
    Tolaney, Sara M.
    Guarneri, Valentina
    Seo, Jae Hong
    Cruz, Josefina
    Abreu, Miguel Henriques
    Takahashi, Masato
    Barrios, Carlos
    McIntyre, Kristi
    Wei, Ran
    Munoz, Maria
    San Antonio, Belen
    Liepa, Astra M.
    Martin, Miguel
    Johnston, Stephen R. D.
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Harbeck, Nadia
    EUROPEAN JOURNAL OF CANCER, 2024, 199
  • [7] Long-term Patient-reported Outcomes from monarchE: Abemaciclib plus Endocrine Therapy for Adjuvant HR+, HER2-, Node-positive, High-risk, Early Breast Cancer
    Harbeck, Nadia
    Guarneri, Valentina
    Seo, Jae Hong
    Cruz, Josefina
    Abreu, Miguel Henriques
    Takahashi, Masato
    Barrios, Carlos
    Mcintyre, Kristi
    Wei, Ran
    Antonio, Belen San
    Liepa, Astra M.
    Martin, Miguel
    Johnston, Stephen R. D.
    Tolaney, Sara M.
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 31 - 31
  • [8] Patients' quality of life and side effect perceptions in monarchE, a study of abemaciclib plus endocrine therapy in adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer
    Tolaney, S.
    Blancas, I.
    Im, Y. -H.
    Rastogi, P.
    Brown, J.
    Shahir, A.
    Zimmermann, A.
    Boyle, F.
    BREAST, 2021, 56 : S20 - S21
  • [9] Efficacy and safety results by menopausal status in monarchE: Adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-high-risk early breast cancer
    Paluch-Shimon, S.
    Neven, P.
    Huober, J.
    Cicin, I.
    Jiang, Z.
    Goetz, M. P.
    Shimizu, C.
    Huang, C.
    Wei, R. J.
    Nabinger, S. C.
    Forrester, T.
    Harbeck, N.
    ANNALS OF ONCOLOGY, 2022, 33 : S151 - S151
  • [10] Efficacy and safety analysis of Chinese patients in monarchE: Abemaciclib combined with adjuvant endocrine therapy for high risk HR+, HER2-early breast cancer.
    Shao Zhimin
    Zhang, Qingyuan
    Song, Chuan-gui
    Ouyang, Quchang
    Liu, Zhenzhen
    Liu, Qiang
    Feng, Jifeng
    Chiu, Joanne Wing Yan
    Tseng, Ling-Ming
    Qian, Chenxi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345